Last reviewed · How we verify
Trimetazidine mimic
This drug inhibits mitochondrial long-chain 3-ketoacyl-CoA thiolase (LC3KAT) to shift cardiac energy metabolism from fatty acid oxidation to glucose oxidation, improving myocardial efficiency without affecting heart rate or blood pressure.
This drug inhibits mitochondrial long-chain 3-ketoacyl-CoA thiolase (LC3KAT) to shift cardiac energy metabolism from fatty acid oxidation to glucose oxidation, improving myocardial efficiency without affecting heart rate or blood pressure. Used for Angina pectoris, Heart failure.
At a glance
| Generic name | Trimetazidine mimic |
|---|---|
| Sponsor | Shenyang Northern Hospital |
| Drug class | Metabolic modulator; fatty acid oxidation inhibitor |
| Target | LC3KAT (long-chain 3-ketoacyl-CoA thiolase) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Trimetazidine mimics the mechanism of action of trimetazidine, a selective inhibitor of the last enzyme in mitochondrial beta-oxidation of long-chain fatty acids. By blocking this enzyme, the drug forces cardiomyocytes to rely more on glucose oxidation for ATP production, which is more oxygen-efficient and beneficial during ischemia or heart failure. This metabolic shift improves cardiac contractility and reduces ischemic injury without hemodynamic side effects.
Approved indications
- Angina pectoris
- Heart failure
Common side effects
- Dizziness
- Headache
- Nausea
- Asthenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |